Showing results (111-120 of 120) with videos related to
Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
British Journal of Cancer|July 9, 2026
Paediatric therapeutic development workshop on medulloblastomaClaudia Montiel Equihua, Joseph S Baxter, Jan J Molenaar, et al.European Journal of Cancer (Oxford, England : 1990)|September 18, 2021
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug AdministrationAndrew D J Pearson, Elly Barry, Yael P Mossé, et al.European Journal of Cancer (Oxford, England : 1990)|July 21, 2020
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, C Michel Zwaan, E Anders Kolb, et al.The Lancet. Oncology|April 3, 2025
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysisAndrew D J Pearson, Claudia Rossig, Crystal L Mackall, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patientsAndrew D J Pearson, Claudia Rossig, Giovanni Lesa, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II TrialJuliet C Gray, Rebekah Weston, Cormac Owens, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma TrialLucas Moreno, Rebekah Weston, Cormac Owens, et al.Pediatric Blood & Cancer|June 13, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy ForumSteven G DuBois, Lucas Moreno, John Anderson, et al.British Journal of Cancer|June 13, 2026
Paediatric Therapeutic Development Workshop on rhabdomyosarcomaJoseph S Baxter, Claudia Montiel Equihua, Jan J Molenaar, et al.Pageof 12